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1 ABSTRACT 
 
 
Clostridium difficile is a Gram-positive, anaerobic bacterium and the leading cause of antibiotic-
associated diarrhea and pseudomembranous colitis. C. difficile modulates the transition from a 
motile to a sessile lifestyle through a mechanism of riboswitches regulated by cyclic diguanosine 
monophosphate (c-di-GMP). Previously described as positively regulated by c-di-GMP, CD2831 
was annotated as putative collagen-binding protein and thus potentially involved in sessility.  
CD2831 is a Sortase substrate and it belongs to the Microbial Surface Components Recognizing 
Adhesive Matrix Molecule (MSCRAMMs) family, a class of virulence factors that has been 
recently reported to play a role also in host immune evasion by binding to human complement 
components. With the overexpression of CD2831 in C. difficile and the heterologous expression 
on Lactococcus lactis surface, here we show that CD2831 is a collagen-binding protein, able to 
bind to immobilized collagen types I, III and V and to the collagen produced by human 
fibroblasts. We also observed that the overexpression of CD2831 increases the ability to form 
biofilm on abiotic surface in both C. difficile and L. lactis. Notably, similarly to other 
MSCRAMMs, we showed that CD2831 binds to the collagen-like domain of the human 
complement C1q, preventing the C1 complex formation and the activation of the complement 
cascade via classical pathway.  
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2 INTRODUCTION 
 
 
 
2.1 Clostridium difficile infection 
 
2.1.1 Epidemiology of Clostridium difficile Infection 
 
Clostridium difficile is a Gram-positive, strictly anaerobic, spore-forming bacterium that 
colonizes the human intestine causing Clostridium difficile infection (CDI). Originally named 
Bacillus difficilis due to its morphology and the issues in finding the appropriate growth 
conditions, it was isolated in 1935 from feces of newborn infants with the description of a new 
commensal anaerobe until the end of 1970s, when it was recognized as the etiologic agent of 
pseudomembranous colitis (Khan and Elzouki 2014). CDI is now well recognized as a cause of 
significant patient morbidity and mortality and as a major burden to the health care costs with 
an attributable mortality ranging from 6.9% to 16.7% in endemic periods (Kwon, Olsen, and 
Dubberke 2015).  
Clinical symptoms of CDI include diarrhea (Bristol stool chart types ranging from 5 to 7), 
pseudomembranous colitis and toxic megacolon (defined as a distention of the colon, usually to 
≥10 cm in diameter, and signs of a severe systemic inflammatory response) (Debast, Bauer, and 
Kuijper 2014). 
CDI is associated to long-term antimicrobial treatments and the 10-35% of antibiotic-associated 
diarrhea is caused by Clostridium difficile. Recent statistical data from Canada, USA and Europe 
indicate an increased incidence and severity of the disease (Khan and Elzouki 2014). This has 
been explained as result of changes in demographic situation, increased use of broad-spectrum 
antibiotics and emergence of hypervirulent C. difficile strains (Freeman et al. 2010).  
Notably, it is important to discriminate between C. difficile colonization and infection. With the 
term “colonization” we refer to the detection of the organism in the absence of CDI symptoms 
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whereas “infection” indicates the presence of C. difficile toxin or a toxigenic strain type and 
clinical manifestations of CDI (Crobach et al. 2018). Clostridium difficile transmission occurs via 
spores but the incubation time between spore ingestion and the occurrence of clinical 
symptoms of the disease is yet to be determined. Asymptomatic carriers, that represent the 
reservoir for environmental contamination, vary from 2% in the community to more than 30% 
in hospitals and long-term care facilities (McFarland, Surawicz, and Stamm 1990). 
2.1.2 Risks factors and clinical features 
 
As mentioned above, the major risk factor for CDI is a long exposure to antimicrobials, 
particularly within the hospital setting. The incidence of CDI in some community hospitals is now 
greater than methicillin-resistant Staphylococcus aureus (MRSA) infections (Miller et al. 2011). 
Almost all antimicrobials, with a particular relevance for the commonly used β-lactam agents, 
have been reported to be associated with CDI and the reason is attributable to their ability to 
alter the commensal intestinal flora (Bartlett 2002). The risk to develop the antimicrobials-
associated CDI is variable and depends on host factors such as the age and the immune system 
function but also on the type and dose of antibiotic, and the duration of the treatment.  
Other risk factors can be recent surgery (transplant, gastrointestinal procedures), treatment 
with proton pump inhibitors and immunosuppressant, underlying debilitating conditions, 
inflammatory bowel disease, prolonged hospitalization (>15 days), and nasogastric tube 
feeding. Elderly patients are at noticeably higher risk, with disease rates for patients over 65 
years of age as much as 20-fold higher than those for younger patients (Surowiec et al. 2006; 
Schroeder 2005). 
The most common clinical presentation of CDI is diarrhea associated with antimicrobials 
therapy. Diarrhea typically occurs from a few days after the initiation of antibiotic treatment to 
as long as 8 weeks after the end of the therapy (Bartlett 2002). For mild-to-moderate disease, 
diarrhea is usually the only symptom. It can be difficult to discriminate between CDI-associated 
diarrhea and other causes of antibiotic-associated diarrhea (AAD) so definitive diagnosis of CDI 
is generally accomplished through laboratory confirmation of the presence of C. difficile toxins. 
Other clinical manifestations of CDI include fever that occurs in ∼28% of cases, leukocytosis 
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(∼50%), and abdominal cramps (∼22%) (Bartlett et al. 1980). Severe forms of the disease are 
characterized of paralytic ileus, which can evolve into toxic megacolon. In this scenario also 
other symptoms co-exist: vomiting, dehydration, lethargy, or tachycardia, in addition to fever 
and abdominal pain. Importantly, CDI can result in pseudomembranous colitis and life-
threatening fulminant colitis, which may lead even to death (Bartlett 2002). 
2.2 Clostridium difficile Pathogenesis 
2.2.1 Spores 
 
The anaerobic nature of C. difficile does not allow the vegetative form to survive in aerobic 
environments so the transmission of CDI relies on the production of dormant spores. After 
ingestion of C. difficile spores, these can pass through the stomach and, upon exposure to bile 
acids, spores germinate into vegetative cells in the small bowel (Poutanen and Simor 2004) (Fig. 
2.1). Spores are not only resistant to oxygen but also to many physical and chemical treatments 
such as heat and the bleach-free disinfectants commonly used in the hospital settings 
(Nakamura et al. 1985; Lawley, Croucher, et al. 2009; Ali, Moore, and Wilson 2011). Being 
metabolically dormant, spores are also intrinsically resistant to antibiotics and attacks from the 
human immune system (Baines et al. 2009; Paredes-Sabja et al. 2012). During the course of the 
disease, C. difficile initiates a sporulation pathway that culminates in the production of dormant 
spores that are responsible of CDI persistence in the patients and dissemination through 
patient-to-patient contact. Indeed, Deakin and its group demonstrated in 2012 that non-
sporulating strains of C. difficile were unable to persist in the colon of the host and be 
horizontally transmitted (Deakin et al. 2012). 
The signals that induce sporulation in vitro and in vivo have not been yet identified. As 
demonstrated for Bacillus subtilis, external stimuli such as nutrients availability, quorum sensing 
or stress factors could be related. In many Bacillus and Clostridium species, the switch to enter 
sporulation is regulated by several orphan histidine kinases that can phosphorylate the master 
transcriptional regulator Spo0A (Higgins and Dworkin 2012). Consistently, SpoOA mutants of C. 
difficile are defective in sporulation (Underwood et al. 2009) and unable to persist and cause 
transmission between mice, suggesting for this factor a pivotal role in sporulation and 
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transmission of CDI (Deakin et al. 2012). Nevertheless, if sporulation is related to hypervirulence 
is still under question (Vohra and Poxton 2011). 
Germination of C. difficile spores is an important step for initiating CDI. Bacterial spore 
germination is induced when bacteria sense the presence of species-specific small molecules 
(germinants). Sodium taurocholate, the main component of bile, chlorine derivatives and the 
amino acid glycine enhance germination of spores into vegetative cells (Wilson, Kennedy, and 
Fekety 1982). In in vivo conditions germination presumably occurs in a neutralized region of the 
intestine as the optimal pH for germination has been shown to be around 6.5-7.5 (Wheeldon et 
al. 2008) and this process may also require the adhesion to semi-solid surfaces since 
experiments demonstrated that enhanced germination is observable on agar rather than in 
liquid broth (Sorg and Sonenshein 2008). 
2.2.2 Toxins  
 
There are more than 400 of Clostridium difficile strains but only the toxigenic ones are able to 
produce disease (Samore et al. 1994). The major virulence factors are in fact the two toxins of 
Clostridium difficile, Toxin A and Toxin B (TcdA and TcdB), which have been extensively studied 
since their first recognition and represent the key factors in C. difficile pathogenesis. TcdA (308 
kDa) and TcdB (270 kDa) are glucosyltransferases, targeting the Ras superfamily of small 
GTPases via glycosylation. These small regulatory proteins are therefore inactivated by the 
irreversible modification leading to disruption of vital signaling pathways in the host cell (Voth 
and Ballard 2005). 
TcdA and tcdB, together with three other genes tcdR, tcdC and tcdE are found in a 19,6 kb 
pathogenicity locus (PaLoc) (Braun et al. 1996). TcdR is homologous to proteins annotated as 
DNA-binding proteins and it is predicted to positively regulate toxins as TcdR expression has 
been shown to enhance toxin promoter activity in E. coli (Moncrief, Barroso, and Wilkins 1997). 
TcdE is thought to be a holin-like protein involved in toxin release (Govind and Dupuy 2012) 
whereas TcdC, whose regulation is inverse to the other PaLoc genes is suggested to act as a 
negative regulator of toxins expression (Hundsberger et al. 1997). The TcdC role is still 
controversial: mutation in the strain R20291 shows increased toxins expression bringing to a 
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hypervirulent strain (Curry et al. 2007), however Cartman et al. demonstrated no change in 
toxins expression upon genetic mutation of TcdC in the R20291 strain (Cartman et al. 2012). This 
may be explained as a possible gene duplication event occurred in tcdA and tcdB genes. 
Notably, in addition to TcdA and TcdB, some strains have shown to present a third toxin, called 
binary toxin (CDT), homologous to other actin-specific ADP-ribosyltransferase of other Clostridia 
(Stubbs et al. 2000; Popoff and Boquet 1988). The genes encoding the binary toxin, ctdA and 
ctdB are not present in the PaLoc region of the chromosome as well as the negative regulator 
gene, ctdR (Carter et al. 2007). In binary toxin, ctdA gene encodes for the CDTa, the enzymatic 
ADP-ribosyltransferase that modifies actin, whereas ctdB encodes for CDTb, which binds to host 
cells and translocates CDTa into the cytosol. CDTb is activated by serine proteases and binds to 
lipoprotein receptors. ADP-ribosylation induces depolymerization of the actin cytoskeleton and 
microtubule-based membrane protrusions which form a network on epithelial cells and increase 
bacterial adherence and colonization (Gerding et al. 2014).  
TcdA and TcdB are internalized into the host cell cytosol via endocytosis through the formation 
of acidic endosomes (Florin and Thelestam 1983). Receptor binding is the first and essential step 
of the cell entry mechanism and TcdA has been shown to recognize the disaccharide Galβ1-
4GlcNac which is found in the I, X and Y blood antigens present in many cells (Tucker and 
Wilkins 1991). Recently, an extensive genome-wide screening on HeLa cells using the CRISPR-
Cas9 approach led to the identification of Frizzled proteins as TcdB receptors (Tao et al. 2016).  
Upon receptors binding, toxins require acidified endosomes to translocate. Lysosomotropic 
inhibitors, such as bafilomycin A and ammonium chloride have been shown to inhibit the 
cytotoxicity of several clostridial toxins and TcdB activity has been abolished by using conditions 
that prevent the fusion between lysosomes and endosomes (Florin and Thelestam 1986). The 
low pH is a required condition for the correct folding of the toxins leading to the exposure of the 
hydrophobic domain (Qa'Dan, Spyres, and Ballard 2000). Once internalized, the prominent 
toxins effect is the profound change in cellular cytoskeleton organization (Mitchell, Laughon, 
and Lin 1987; Thelestam and Bronnegard 1980). Several studies from Just and colleagues 
demonstrated that TcdB was able to glucosylate the GTPases RhoA, Rac and Cdc42 using UDP-
glucose as cosubstrate and that TcdA could modify RhoA with the same mechanism, concluding 
   11 
   
that both the toxins are glucosyltransferases capable of inactivating small GTPases within the 
cell (Just, Selzer, et al. 1995; Just, Wilm, et al. 1995). The phenotype in infected cells results in 
cellular rounding due to actin condensation, membrane blebbing and eventually in apoptosis. 
Importantly, the decline in F-actin results also in tight junction disruption between intestinal 
epithelial cells (Nusrat et al. 2001). Both TcdA and TcdB induce the influx of neutrophils that 
causes inflammation typical of pseudomembranous colitis. This may be due to tight junctions 
disruption but also to stimulation of cytokine expression and macrophage derived TNF-α (Kim et 
al. 2002; Kelly et al. 1994) (Fig 2.1). 
A study from our group showed the importance of toxins not only as effectors of toxicity but 
also in facilitating the bacterial colonization. Indeed, TcdA-mediated subversion of cell polarity 
facilitates C. difficile adhesion and translocation of Caco-2 monolayer (Kasendra et al. 2014). 
Other studies demonstrated that when Binary Toxin is present, strains can develop more severe 
diarrhea and that Toxin A-/B- Binary Toxin positive strains have been isolated from symptomatic 
patients (Geric et al. 2003; Barbut et al. 2005). Despite this, one study shows that Toxin A-/B- 
strains which express binary toxin are non-pathogenic in hamsters and do not cause the same 
level of mucosal damage in the rabbit as toxin positive strains do (Geric et al. 2006). 
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Fig. 2.1 | Clostridium difficile infection of the human gut 
Once ingested, spores can survive in the stomach environment and germinate into the small bowel upon 
exposure to bile acids. C. difficile vegetative cells arrive in the colon, adhere to the gut mucosa and 
proliferate. Toxins production leads to epithelial integrity perturbation (1) and to production of tumour 
necrosis factor-alpha and proinflammatory interleukins. This results in increased vascular permeability, 
neutrophil and monocyte recruitment (2), opening of epithelial cell junctions (3) and epithelial cell 
apoptosis (4). Local production of hydrolytic enzymes leads to connective tissue degradation, conducting 
to colitis, pseudomembrane formation (5) and diarrhea (Poutanen and Simor, 2004). 
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2.2.3 Colonization and adhesion to the host 
2.2.3.1 S-layer and adhesins 
 
In order to induce its pathogenicity, vegetative C. difficile cells need to be implanted in the gut 
epithelial cells, which are protected by a layer of dense mucus. Once adhered to the mucus 
layer, C. difficile can reach the enterocytes present in the small bowel and colon by means of its 
multiple adhesins (Deneve et al. 2009). The hydrophobic nature of C. difficile cell surface as well 
as the positive charges distributed within the cell wall, may play a role during the gut 
colonization via interaction with negatively charged intestinal cells (Borriello and Wilcox 1998; 
Borriello 1998). 
The crossing of the first barrier represented by the mucus layer involves flagellar components 
such as cap protein (FliD) and flagellin (FliC) (Deneve et al. 2008). Important is also the presence 
of proteolytic enzymes such as hyaluronidase and collagenase that can contribute to the release 
of essential nutrients facilitating C. difficile establishment in the gut (Seddon, Hemingway, and 
Borriello 1990).  
Pivotal is the contribution given by Surface Layer proteins (SLPs), which mediate the adherence 
to the mucus and to epithelial cells of the gut. SLPs are part of the S-layer that completely cover 
the outer cell surface of the bacterium. Specifically, the S-layer consists of two proteins, the 
high-molecular weight P47 (HMW) and the low-molecular weight P36 (LMW) that derive from 
SlpA precursor clevage and interact to each other in a heteromeric complex (Emerson et al. 
2009). HMW SlpA can strongly associate to human and murin gastrointestinal tissues and to 
some extracellular matrix components such as collagen, thrombospondin and vitronectin 
(Emerson et al. 2009; Janoir et al. 2007). 
Other surface proteins likely involved in the host colonization include the heat shock protein 
GroEL (Hennequin, Collignon, and Karjalainen 2001; Hennequin et al. 2001) the adhesin Cwp66 
(Clostridial Wall Protein, 66 kDa) that mediates in vitro adherence to Vero cells (Pechine, 
Deneve-Larrazet, and Collignon 2016; Wright et al. 2005) and the lipoprotein CD0872 (Kovacs-
Simon et al. 2014). 
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2.2.3.2 MSCRAMM family proteins 
 
As other pathogens, C. difficile targets a wide variety of host molecules via multiple 
mechanisms, including binding to components of the host extracellular matrix (ECM). The 
surface proteins known to mediate adhesion to ECM are designated as “Microbial surface 
components recognizing adhesive matrix molecules” (MSCRAMMs). Their role could be crucial 
in C. difficile pathogenesis as the disruption of epithelial barrier caused by the toxins determines 
the accessibility to the underlying matrix and therefore favors bacterial colonization (Fig 2.1). 
Fibronectin-binding protein A (FbpA) and Collagen-binding protein A (CbpA) are examples of C. 
difficile MSCRAMMs playing a role in this mechanism (Hennequin et al. 2003; Tulli et al. 2013).  
The most characterized collagen-binding MSCRAMM is the Staphylococcus aureus Cna protein. 
CNA-like collagen-binding proteins have been identified in other bacteria, among which are ACE 
(adhesin of collagen from Enterococcus faecalis) (Rich et al. 1999), Acm (adhesin of collagen 
from Enterococcus faecium) (Nallapareddy, Weinstock, and Murray 2003) and CNE (collagen-
binding protein from Streptococcus equi) (Lannergard, Frykberg, and Guss 2003). These proteins 
share the Cna domain organization, however the specific binding mechanisms for each collagen 
adhesin may be somewhat different.  
A second role for MSCRAMMs has been identified in the host immune system evasion with the 
binding to the complement component C1q. The human complement C1q presents a shape 
resembling a bunch of flowers, with six peripheral globular heads, each connected by fibrillar 
strands to a central bundle of collagen-like fibers (Reid 1979; Reid, Gagnon, and Frampton 
1982). Globular regions of C1q recognize the Fc region of antibodies on the bacterial surface 
(Hughes-Jones and Gardner 1979) and the central collagen-like structure activates the 
complement cascade via the classical pathway through the interaction with the other two 
components of the C1 complex, C1s and C1r. Besides complement activation, C1q is also able to 
enhance phagocytosis independently from C1r and C1s (Bobak et al. 1987) and this activity 
requires the collagen-like tail of C1q (Bobak, Frank, and Tenner 1988; Thielens et al. 2017).  
The collagen-binding protein Cna from Staphylococcus aureus, and other similar proteins of 
Gram-positive bacteria, can bind to the “collagenous domain” of C1q. Interaction of Cna with 
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C1q has been shown to prevent the binding of C1r to C1q thus inhibiting the C1 complex 
formation and consequently the classical complement pathway activation (Kang et al. 2013). 
 
 
 
Fig. 2.2 | Schematic representation of MSCRAMMs interfering with C1r/C1s binding to C1q 
Binding of dimers of C1s and C1r to the collagen-like domain of the C1q stalk is required for 
initiation of the human complement cascade via classical pathway (A). When MSCRAMMs 
proteins such as Cna of S. aureus interact with antibodies-associated C1q, the binding of C1s and 
C1r to C1q as well as the activation of the complement cascade is prevented (B). 
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2.2.4 C-di-GMP regulation 
 
An important role in regulating C. difficile colonization is played by the second messenger c-di-
GMP whose levels can control the expression of proteins involved in bacterial motility and 
sessility. C-di-GMP acts by binding riboswitches, tridimensional structures present at the mRNA 
level located upstream of the target genes (Peltier and Soutourina 2017). C. difficile encodes a 
large number of diguanylate cyclases and phosphodiesterases that are responsible for the 
synthesis and degradation of c-di-GMP, respectively, and 16 predicted c-di-GMP-responsive 
riboswitches have been identified in C. difficile genome (Bordeleau et al. 2011; Sudarsan et al. 
2008; Soutourina et al. 2013). C-di-GMP controls bacterial physiology and virulence by 
modulating the expression levels of tcdA and tcdB, as well as that of tcdR, which encodes an 
alternative sigma factor that activates tcdA and tcdB expression (McKee et al. 2013; Martin-
Verstraete, Peltier, and Dupuy 2016). In many bacterial species, including C. difficile, c-di-GMP 
controls lifestyle switch from free-living motile state to biofilm communities (Romling, Galperin, 
and Gomelsky 2013; Purcell and Tamayo 2016). In particular, c-di-GMP negatively regulates 
flagellar swimming motility and positively regulates expression of putative adhesins and type IV 
pili (TFP) biosynthesis. Indeed, TFP have been recently shown to be fundamental for adherence 
and persistence of C. difficile in a mouse model of infection (Purcell et al. 2016; Bordeleau et al. 
2015; Purcell et al. 2012; McKee et al. 2018) (Fig. 2.3 A). 
Interestingly, a type I riboswitch that is activated at low levels of c-di-GMP, was found upstream 
of the C. difficile protease ZmpI (CD2830), whereas the close gene coding for the putative 
collagen-binding adhesin CD2831 (Sebaihia et al. 2006) presents a type II c-di-GMP riboswitch, 
activated at high levels of cellular c-di-GMP. CD2831 and another c-di-GMP controlled putative 
adhesin, CD3246, are recognized and cleaved by ZmpI. This mechanism suggests that expression 
of ZmpI could be upregulated in the presence of low concentration of c-di-GMP, whereas the 
expression of CD2831 may be upregulated in presence of high levels of intracellular c-di-GMP 
(Soutourina et al. 2013). Consistently, it was demonstrated that at low c-di-GMP levels, ZmpI is 
produced and it cleaves the low amount of CD2831 and CD3246, thus limiting bacterial adhesion 
to the host (Hensbergen et al. 2015; Peltier et al. 2015; Corver et al. 2017) (Fig. 2.3 B). 
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C-di-GMP positively regulates C. difficile biofilm formation, and high level of intracellular c-di-
GMP in the 630 strain results in a more robust biofilm (Soutourina et al. 2013; Purcell et al. 
2017). There are many studies and evidences demonstrating the ability of C. difficile to form 
biofilm in vitro. C. difficile biofilm on abiotic surface varies between strains even though no 
correlation between biofilm robustness and virulence has been found (Ethapa et al. 2013; 
Pantaléon et al. 2018). In the biofilm asset, bacteria have been shown to be embedded in a 
matrix rich of extracellular DNA, polysaccharides and proteins, including toxin A and B. Besides 
c-di-GMP, biofilm formation process is modulated by the master regulator Spo0A, as in R20291 
strain a genetic inactivation of spo0A exhibits decreased biofilm formation (Dawson et al. 2012). 
Also Cwp84, flagella, TFP and the quorum-sensing regulator LuxS, are all required for maximal 
biofilm formation by C. difficile (Pantaleon et al. 2015; Maldarelli et al. 2016; Ethapa et al. 2013). 
Importantly, evidences support C. difficile biofilm formation in vivo: observations in a mouse 
model showed that C. difficile forms clumps associated with damaged tissue suggesting the 
formation of microcolonies (Lawley, Clare, et al. 2009). Also, infected hamsters and mice have 
been reported to present aggregation or clusters of C. difficile (Buckley et al. 2016; 
Soavelomandroso et al. 2017) and recent studies show the presence of C. difficile biofilm 
communities in association with the gut mucus layer (Semenyuk et al. 2015; Soavelomandroso 
et al. 2017).  
Although many advances have occurred in understanding c-di-GMP effects on bacterial 
physiology, the stimuli and the mechanisms present upstream the modulation of c-di-GMP in C. 
difficile are still unknown.  
In this study we establish that the c-di-GMP regulated CD2831 is a collagen-binding protein 
contributing to C. difficile adhesion to the host extracellular matrix. Gene overexpression of 
CD2831 significantly increased biofilm formation in vitro, suggesting a role for CD2831 in the 
process of biofilm formation. Moreover, as other MSCRAMMs, CD2831 can bind to human 
complement C1q and thus potentially be involved in host immune evasion mechanisms. 
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Fig. 2.3 c-di-GMP regulates C. difficile lifestyle 
(A) Second messenger c-di-GMP is synthesized by proteins with diguanylate cyclase activity and 
degraded by phosphodiesterases. C-di-GMP can act on effectors involved in flagellar motility, 
adhesion and virulence factors expression. In particular, increased c-di-GMP levels 
downregulate flagellar motility whereas upregulate expression of adhesines and other 
molecules involved in sessility and biofilm formation. (B) c-di-GMP inversely modulates CD2831 
and the protease CD2830 (ZmpI) by targeting riboswitches located upstream of the target 
mRNA. Binding of c-di-GMP allosterically modify the riboswitch, changing the accessibility of 
ribosomes to the ribosome-binding site. CD2831 translation is enhanced after c-di-GMP binding, 
whereas ZmpI translation is repressed upon c-di-GMP binding. 
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3 EXPERIMENTAL PROCEDURES 
 
 
3.1 Bacterial strains and growth conditions 
 
C. difficile 630Δerm strain (an erythromycin-sensitive derivative of C. difficile strain 630) was 
grown anaerobically (10 % H2 , 10 % CO2 and 80 % N2) at 37 °C in Brain-Heart Infusion (BHI) 
(ThermoFisher, Massachussetts, USA) broth or agar supplemented with 0.05% L-cysteine and 
0.5% yeast extract (BHIS). When necessary, C. difficile cultures were supplemented with D-
cycloserine (25 µg/ml) and/or thiamphenicol (20 µg/ml) (Sigma, Missouri, USA). E. coli HK100 
cells and BL21(DE3)T1R strains, used to clone and express CD2831, were cultured at 37°C in 
Luria-Bertani (LB) broth supplemented with 100 µg/ml ampicillin. L. lactis MG1363 strain was 
cultured at 30 °C in M17 growth medium supplemented with 0.5% glucose and, when required, 
with 20 µg/ml chloramphenicol. Anhydrotetracycline (aTC) was used from 10 to 100 ng/ml for 
induction of the pTet promoter in C. difficile. 
3.2 Cloning, expression and purification of CD2831 
 
CD2831 domain prediction was assessed with a blast search against the CDD database available 
at NCBI. Localization of collagen-binding domains was further investigated with Pfam 
(https://pfam.xfam.org/). For the expression of recombinant CD2831 full length and subdomain 1 
(157-432), 2 (432-840), 3 (311-940), 4 (157-830), 5 (32-830) and 6 (594-940), the corresponding 
sequences were amplified by PCR using chromosomal DNA from C. difficile 630 strain as 
template. The PCR products were cloned in pET21 vector (Novagen, Wisconsis, USA) using the 
PIPE method (Klock et al. 2008). BL21(DE3)T1R chemically competent cells were used for 
expression of the N-terminal His-tag proteins. A single colony of E. coli BL21(DE3)T1R strain 
expressing CD2831 was inoculated in LB containing 100 μg/ml ampicillin and grown overnight at 
37°C. Bacterial suspension was diluted in fresh HTMC medium supplemented with 100 μg/ml 
ampicillin and grown for 30 hours at 25 °C. Proteins expression was induced by adding 0.5 mM 
Isopropyl β-D-thiogalactopyranoside (IPTG) (Sigma, Missouri, USA). Recombinant CD2831 His-
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tagged proteins were purified by affinity chromatography on Ni2+-NTA Superflow (Qiagen, 
Italy). The purity of the proteins was checked by SDS-PAGE followed by Coomassie Blue staining 
and the proteins concentration was determined by BCA reagents (ThermoFisher, 
Massachussetts, USA). 
3.3 Construction of CD2831 overexpressing strains of C. difficile 
 
The CD2831 gene was amplified from C. difficile strain 630Δerm genomic DNA using Phusion® 
High-Fidelity DNA Polymerase (NEB, England, UK). Region containingribosome-binding site (RBS) 
of SlpA protein of C. difficile was included in the forward primer before the ATG start codon 
(primer Fw: CGAGCTCAATATAATGTTGGGAGGAATTTAAGAAATGAAGAAAGGAAATAGAAAGGCA 
and primer Rv GACTAGTCTAATTTGTATTTTTATTTCTTCT). PCR product was digested with SacI-
SpeI and cloned into pMTL960 derivative vectors (Fagan and Fairweather 2011) containing 
either cwp2 constitutive promoter (producing pCwp2-2831) or pTet inducible promoter 
(producing pTet-2831).  
3.4 E. coli-C. difficile conjugation 
 
Overnight cultures of E. coli SM10λpir carrying CD2831 expression vector were harvested and 
pellets were resuspended in 200 μl of C. difficile overnight culture in the anaerobic cabinet. The 
mixed bacterial suspension was then spotted onto BHIS agar plates and conjugation proceeded 
for 8 hours at 37 °C. 1:5 dilutions were plated onto BHIS agar containing 20 μg/ml thiamphenicol 
for plasmid selection and 250 μg/ml cycloserine for E. coli growth inhibition. Plates were grown 
overnight at 37 °C in the anaerobic cabinet. Transconjugants were picked and streaked onto 
fresh selective plates twice to purify C. difficile containing CD2831 overexpressing plasmids from 
E. coli. 
3.5 Generation of Lactococcus lactis expressing CD2831 strain 
 
The construction of L. lactis strain expressing the C. difficile protein CD2831 was performed as 
previously described (Tulli et al. 2013). Briefly, the CD2831 gene was amplified by PCR using 
chromosomal DNA from C. difficile 630Δerm strain as template (primer1: 5’- 
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GAGGTTAAGGCTAACGGTTCAGAATTAGGAGAGAATAGTCAGATTCAAAG -3’ and primer2: 5’- 
ACCTGTTGATGGTAATACTGGTGGATTTACCAAAGTATCATCTTTAAC -3’) and cloned in pAM401 
expression vector (Buccato et al. 2006). The coding sequence for the leader peptide (1-93 bp) 
and the PPKTG-motif at C-terminal (2817-2829 bp) of CD2831 were substituted with the same 
regions of the GAS emm1 gene encoding the streptococcal M1 protein to ensure the surface 
exposure in L. lactis as described by Edwards et al. (Edwards et al. 2008). pAM401-M1 was used 
as template to amplify the expression vector containing the leader peptide and the C-terminal 
of M1 protein (Primer3: 5’-GATAGTAATGTAGGTCAATTACCATCAACAGGTGAAACAGCTAACCCA-3’; 
primer4: 5’-GTATCTGCGAAAGTATTTGAACCGTTAGCCTTAACCTCTGTTTGATTCGC-3’). The two 
products were assembled by PIPE method in E. coli HK100 cells and the resulting vector was 
introduced in L. lactis subspecies cremoris MG1363 strain by electroporation. 
3.6 Production of polyclonal antibody against CD2831 
 
Rabbits were immunized three times, 2 weeks apart, with 10 μg of recombinant CD2831 in the 
presence of aluminum hydroxide. The immune serum was obtained 14 days after the last 
immunization. All animal experiments were performed in accordance with relevant guidelines 
and regulations established by the Italian law, including the approval of the local Animal 
Welfare Body followed by authorization of Italian Ministry of Health.  
3.7 Cell fractionation and protein analysis 
 
To obtain cell wall-associated proteins of C. difficile the following protocol was applied. Bacteria 
were grown until exponential phase, harvested by centrifugation at 3000 x g for 10 minutes and 
washed in Tris-sucrose buffer (TS: 10 mM Tris-HCl pH 6.9, 10 mM MgCl2, 0.5 M sucrose). Cells 
were resuspended in TS buffer, protease inhibitors cocktail (Complete Mini EDTA-free, Roche) 
and 250 μg/ml of mutanolysin (Sigma, Missouri, USA) and digestion was allowed to proceed for 
2 hours at 37 °C with gentle agitation. The majority of intact protoplasts were removed by 
centrifugation at 3000 x g for 30 minutes. The supernatant was then subjected to 
microcentrifugation at 17000 x g for 30 minutes to remove cell debris and any remaining 
protoplasts. The supernatant containing the solubilized cell surface proteins was recovered. 
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Proteins were separated by SDS-PAGE electrophoresis using NuPage Gel System (ThermoFisher, 
Massachussetts, USA), according to the manufacturer’s instructions. Samples were transferred 
to nitrocellulose membranes for Western blot analysis. After blocking with PBS containing 
0.05% Tween 20 (PBST) and 10% w/v skim milk powder (Sigma, Missouri, USA), proteins were 
detected with anti-CD2831 serum followed by the HRP-conjugated secondary antibodies (DAKO, 
Glostrup, Denmark) diluted in PBST and 3% w/v skim milk powder. Bands were visualized with 
Super Signal® West Pico Chemiluminescent Substrate (Thermo Scientific, Massachussetts, USA). 
3.8 Flow cytometry analysis  
 
C. difficile  and L. lactis cultures were harvested at 6000 x g for 1 minute and washed twice with 
PBS. The pellet was resuspended in 4% (v/v) formaldehyde (Carlo Erba Reagents, Italy) in PBS 
and incubated for 30 minutes at room temperature. Pellets were washed twice and incubated 
with rabbit anti-CD2831 serum diluted 1:100 for 1 hour at room temperature. After two washes 
with PBS, bacterial pellets were incubated with Alexa Fluor 647-conjugated secondary anti-
rabbit antibody (Thermo Scientific, Massachussetts, USA) diluted 1:500 for 30 minutes at room 
temperature in the dark. All washing steps and antibodies dilutions were performed using 1% 
(w/v) bovine serum albumin (BSA) in PBS. Bacterial samples were analyzed by BD FACS Canto II 
system (BD Bioscience, USA). 
3.9 Proteins ELISA 
 
96-well MaxiSorp PS Immuno F96 plates (Thermo Scientific, Massachussetts, USA) were coated 
overnight at 4 °C with 100 μl collagen I, III , V or human C1q (Sigma, Missouri, USA) at the final 
concentration of 10 μg/ml. Plates were washed three times with 0.9% NaCl + 0.05% Tween-20 
(NaCl-T) and blocked with 3% (w/v) BSA + 0.05% Tween + in PBS for 2 hours at 37 °C. Plates 
were washed three times with NaCl-T. Recombinant C. difficile proteins were two-fold serially 
diluted in PBS, then added to the collagen/C1q-coated wells and incubated for 1 hour at 37 °C. 
Following incubation, the wells were gently washed three times with NaCl-T. Anti-CD2831 
antibodies diluted 1:500 in 1% BSA/PBS were added to each well and incubated for 1 hour. 
Wells were washed three times with NaCl-T before incubation with anti-rabbit HRP-conjugated 
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secondary antibodies (DAKO, Glostrup, Denmark) diluted 1:2.000 in 3% BSA/PBS  w/v for 1 hour. 
Wells were washed three times in NaCl-T and 50 μl OPD substrate (5 ml 0.1 M citric acid, 5 ml 
0.2 M Na2HPO4, 10 ml H2O, 1 OPD tablet (Sigma, Missouri, USA), 8 μl H2O2) was added to each 
well. Plates were incubated at room temperature for 15 minutes and the reaction was stopped 
with 50 μl of 3M H2SO4 per well. The optical density at 450 nm was determined using a 
microplate reader. 
The competition assay was performed by the procedure described above, with the following 
alterations: two-fold diluted CD2831 protein was pre-incubated with 1% Normal Human Serum 
(NHS) (Sigma, Missouri, USA) at RT for 1 hour. The mixture was subsequently added to 
microtiter plates previously coated overnight at 4 °C with purified IgM (1 μg/well). Rabbit 
antibodies against C1q, C1r and C1s (Sigma, Missouri, USA) diluted 1:250 in 1% BSA/PBS were 
used to detect proteins deposition. C1q-depleted serum (Sigma, Missouri, USA) was used as 
negative control. Detection was performed as described above. 
3.10 Protein binding and bacterial adhesion assay to IMR-90 cells  
 
IMR-90 human fibroblasts (ATCC, Virginia, USA) were cultured in Eagle’s Minimum Essential 
Medium (EMEM) (ATCC, Virginia, USA) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) (Thermo Scientific, Massachussetts, USA) and antibiotics at 37 °C with 5% CO2. Cells 
were seeded onto 8-well chamber slides or 96-well plates coated with collagen I  (BD BioCoat, 
England, UK) and cultured for 3 days to induce ECM protein production.  
Cells were then incubated with serially diluted recombinant CD2831 proteins (0.08-10 µM). 
After washing to remove the unbound proteins, cells were fixed with 4% (v/v) formaldehyde in 
H2O for 30 minutes at RT. Samples were washed and incubated with rabbit anti-CD2831 sera 
(1:500 in PBS/BSA) for 1 hour at RT. After multiple washes, samples were incubated with FITC-
conjugated goat anti‐rabbit IgG (1:500 in PBS/BSA) for 1 hour at RT. Binding of the proteins was 
quantified with a microplate fluorescence reader. 
Similarly, for bacterial adhesion assay, L. lactis or C. difficile strains were grown until exponential 
phase, resuspended in DMEM medium and added to the microtiter wells. After 2 hours of 
incubation at 37 °C in anaerobic conditions, plates were washed with PBS and fixed with 4% 
   24 
   
(v/v) formaldehyde in H2O for 30 minutes at room temperature. After three washes with PBS, 
samples where incubated with 3% (w/v) BSA in PBS for 30 minutes and immunofluorescence 
staining was performed as follows. To detect collagen-adhering bacteria, an anti-C. difficile 630 
polyclonal serum diluted 1:500 and a mix of anti- Collagen I, III and V  (Santa Cruz, Texas, USA) 
diluted 1:250 in 1% (w/v) BSA in PBS were added for 1 hour, followed by washes and incubation 
with Alexa Fluor-conjugated secondary antibodies 1:500 in 1% (w/v) BSA in PBS for 30 minutes. 
Adhering bacteria were measured by using a fluorescence plate reader. For microscopy 
visualization, wells were incubated with Alexa-Fluor-conjugated phalloidin (Thermo Scientific, 
Massachussetts, USA) and DAPI (Sigma, Missouri, USA) and glass coverslips were mounted with 
ProLong® Gold antifade reagent and analysed with Zeiss LSM710 confocal microscope.  
3.11 Biofilm formation assay  
 
Overnight cultures of C. difficile or L. lactis were diluted 1:100 into fresh medium containing 0.1 
M glucose and 1 ml was seeded on 24-well or 48-well polystyrene plates (Sigma, Missouri, USA) 
for the desired time. To prevent evaporation of liquid, plates were wrapped with parafilm. 
Measurement of biofilm biomass was assessed using crystal violet as previously described 
(Varga, Therit, and Melville 2008; Ethapa et al. 2013). After the required incubation, wells were 
gently washed with sterile PBS and then allowed to dry for 10 minutes. The biofilm was stained 
with filter-sterilized 0.2% crystal violet (Sigma, Missouri, USA) and incubated for 30 minutes at 
37 °C. Crystal violet was removed from the wells, followed by two washes with sterile PBS. The 
dye was extracted by adding 1 ml methanol to each well and incubation for 30 minutes at room 
temperature in aerobic conditions. The methanol-extracted dye was diluted 1:2 or 1:10 and 
absorbance at 570 nm was measured using a microplate reader. 
3.12 Confocal microscopy analysis of biofilm formation 
 
For microscopy visualization of microbial biofilm, bacteria were grown in 8-well glass chamber 
slides (BD Biosciences, New Jersey, USA) in BHIS supplemented with 0.1 M glucose, at 37 °C in 
anaerobic conditions for 72 hours. The wells were washed twice, and before removing from the 
anaerobic chamber, bacteria were fixed with 4% (v/v) formaldehyde in H2O for 30 minutes. 
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Extracellular DNA and nuclei were stained by using DAPI (ThermoFisher, Massachusetts, USA) 
diluted 1:5000 in PBS for 30 minutes. Chamber slides were mounted with ProLong Gold Antifade 
Reagent (ThermoFisher, Massachusetts, USA) and analyzed with a Zeiss Observer LSM710 
confocal microscope. 
3.13 Electron Microscopy 
 
A 5 μl aliquot of purified proteins CD2831 and/or C1q (10 ng/µl) were charged on a 300-mesh 
copper TEM grid (Agar Scientific, Stansted, UK). After 1 minute of adsorption the excess was 
blotted with Whatman filter paper and the samples were counterstained with Nano-W 
(Nanoprobes, Yaphank, NY, USA) for 30 seconds. The images were acquired at 120000x 
magnification using a TEM FEI Tecnai G2 spirit microscope operating at 100kV and equipped 
with an 2K × 2K CCD Veleta (Emsis, Germany).  
3.14 Statistical analysis 
 
At least two independent experiments, run under the same conditions, were performed for all 
studies.  Results were analyzed with GraphPad Software (La Jolla California, USA) by applying 
the Student t test for unpaired data. P ≤ 0.05 was considered statistically significant (*,P ≤ 0.05; 
**, P ≤ 0.01; ***, P ≤ 0.001, ****, P≤ 0.0001). 
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4 RESULTS 
 
 
 
4.1 CD2831 structure and domains prediction  
 
CD2831 is a protein codified by the homonymous gene and consists of 972 amino acid residues. 
The protein was first identified when the complete genome sequence of C. difficile 630 strain was 
determined and it was annotated as a putative collagen-binding adhesin (Sebaihia et al. 2006). 
CD2831 protein presents an N-terminal putative leader peptide of 31 amino acids followed by a 
short repeat region (AA 56-157). Despite a previous in silico analysis of CD2831 identified the 
presence of a central “Collagen-Hug” motif comprised between amino acids L173 and G459 
(Hensbergen et al. 2015), our study revealed the presence of a collagen-binding superfamily region 
spanning from residues 225 to 797. Weak sequence similarities (20% amino acid identity) to the S. 
epidermidis Adhesin Sdrg and the S. pyogenes T6 Backbone Pilin were detectable in the 165-460 
and 461-820 regions respectively, suggesting the typical MSCRAMM structural organization in IgG-
like sub-domains. Localization of putative collagen-binding domains was further investigated and 
predicted the location of two collagen-binding domains (CBDs), from here on indicated as CBD 1 
and 2. The first extends from amino acids N334 to D431 whereas CBD2 corresponds to the region 
from G467 to E592. The CBDs are followed by a region of 110 amino acids rich in Proline that has 
been described to be recognized and cleaved by the endogenous metalloprotease ZMP1/CD2830 
(Hensbergen et al. 2015; Peltier et al. 2015). Interestingly, as described above, CD2831 and ZmpI 
are inversely regulated by c-di-GMP through a riboswitches mechanism. The C-terminal region of 
CD2831 encompasses an LPXTG-like motif (PPKTG) recognized by the Sortase B enzyme, which is 
responsible for the cell-wall proteins attachment to the peptidoglycan (Peltier et al. 2015). The 
sortase motif is followed by a hydrophobic region, most probably representing the transmembrane 
domain (Fig. 4.1).  
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 Fig. 4.1 | Domain organization of CD2831. 
Schematic representation of CD2831 domains organization displays the Leader Peptide at the N-terminus (orange), necessary for the export of the 
full-length precursor across the cytoplasm. CD2831 also contains a Short Repeat Region (yellow) in which repeated amino acids sequences are 
marked in bold, two Collagen-binding domains (blue) and a Proline-rich region (green) recognized by the protease ZmpI, which cleaves within the 
seven NPP amino acids sequences of the domain. The protein is cleaved between the threonyl and glycil residues of the PPKTG motif and 
transferred to the cell-wall peptidoglycan by Sortase B enzyme. The charged tail and the hydrophobic domain (TMD) at the C-terminus (red) prevent 
the protein from release into the extracellular milieu. 
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4.2 Recombinant CD2831 and subdomains containing CBD1 and CBD2 bind to 
native collagen produced by cells and to collagen types I, III and V 
 
To investigate the predicted collagen-binding activity of CD2831, the sequences coding for the full-
length CD2831 and six different portions of the protein were cloned and expressed in E. coli. 
Subdomains 1 (157-432) and 2 (432-830) include the N-terminal region containing only the CBD1 
and the C-terminal region presenting CBD2, respectively. CD2831 subdomains 3 (311-940), 4 (157-
830) and 5 (32-830) encompass both the CBDs with subdomain 3 including also the Pro-rich and 
subdomain 5 the short repeat region. Subdomain 6 (594-940) represents the C-terminus of CD2831 
and, lacking any CBD, was used as negative control in the binding assay (Fig. 4.2 A).  
After purification, full length CD2831 and subdomains were tested in their binding activity toward 
native collagen produced by human cells. For this, confluent IMR90 human fibroblasts were 
cultured on 96-well plates for three days. In these conditions IMR90 cells are known to produce a 
considerable amount of extracellular matrix components (ECM), with a relevant presence of 
collagen.  
Experiments using IMR90 showed that CD2831 displays a dose-dependent binding activity to 
native collagen. Subdomains 3 (311-940), 4 (157-830) and 5 (32-830), encompassing the CBD1 and 
CBD2 portions, showed a binding kinetic similar to the full-length protein, confirming the predicted 
collagen binding activity. Addition of the short repeat region at N-terminal (subdomain 5) or the 
Proline-rich region (subdomain 3) at C-terminal showed no impact on binding activity, further 
confirming that the minimal domain mediating the interaction to collagen resides in the CBD1 and 
CBD2 portions of the protein. When expressed individually, CBD1 and CBD2 (subdomains 1 and 2) 
showed higher binding activity compared to the full-length protein. portions of the protein. 
Unexpectedly, when expressed individually, CBD1 and CBD2 (subdomains 1 and 2) showed a higher 
binding activity compared to the full-length protein (Fig. 4.2 B). Equal recognition of each domain 
from CD2831 anti-sera was confirmed by dot blot (Fig. 4.2 C). 
Full length recombinant CD2831 binding to native collagen was also visualized by 
immunofluorescence showed in Fig. 4.2 D, which displays a spatial co-localization between CD2831 
(green) and native collagen (red) produced by human fibroblasts IMR90. 
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Fig. 4.2 | Binding of recombinant CD2831 full length protein and subdomains to IMR90 cells. 
A. Schematic representation of CD2831; Blue, black and grey lines indicate length of recombinant CD2831 
subdomains designed for the study. B. Human fibroblasts IMR90 were cultured into collagen I-coated 96 
well plates for three days after seeding. Cells were then incubated with serially diluted recombinant CD2831 
proteins ranging from 0.08 to 10 µM. Binding of the proteins was detected by using anti-CD2831 and 
secondary Alexa Fluor antibodies and quantified by a multi-well fluorescent reader. C. Dot Blot on 25 and 50 
ng of recombinant proteins spotted on nitrocellulose membrane. Proteins were revealed by using rabbit 
anti-sera raised against the full length recombinant CD2831 diluted 1:500. D. Immunofluorescence of 1 µM 
of CD2831 full-length (rCD2831) (green) binding to collagen (red) produced by IMR90 cells. Collagen staining 
results from a mix of antibodies against Collagen types I, III and V in a 1:1:1 ratio. 
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To further define the affinity of CD2831 to collagens types known to be more represented in the 
gut tissue (Graham et al. 1988), collagen-binding activity of CD2831 full-length and subdomains 1 
and 2 (containing single CBD) was further investigated through ELISA test on immobilized collagen 
type I, III and V. Recombinant proteins in a range of concentrations between 0.15 and 2 M 
showed a dose-depending binding activity to Collagens types I, III and V. All the recombinant 
proteins showed a higher binding affinity to collagen type V, whereas comparable was the affinity 
to collagens types I and III. Consistent with what observed in the experiments described above 
with human cells, binding of single CBD (subdomains 1 and 2) revealed to be higher compared to 
the full-length CD2831 (Fig. 4.3). 
 
 
Fig. 4.3 | Binding of recombinant CD2831 full-length protein and subdomains to Collagen. 
ELISA plates were coated with 10 μg/ml of purified collagens and incubated with serially diluted 
recombinant CD2831 proteins ranging from 15 nM to 2 µM. Binding of the proteins was detected by anti-
CD2831 polyclonal serum diluted 1:500, followed by HRP-conjugated-secondary antibody. CWP25 protein 
was used as negative control. CD2831 CBD1 and CD2831 CBD2 represent subdomains 1 and 2 previously 
described. 
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4.3 Expression and cleavage of CD2831 in CD630Δerm  
 
As previously mentioned, CD2831 presents at its C-terminal a 111 amino acids sequence rich in 
prolines that is recognized and efficiently cleaved by the endogenous secreted metalloprotease 
ZmpI which eventually brings to secretion of the protein (Schacherl et al. 2015). In in vitro 
conditions, c-di-GMP levels that inversely regulate CD2831 and ZmpI are almost undetectable and 
this results in a large protease production with a subsequent low presence of CD2831 in the cell 
wall (Peltier et al. 2015). 
Cell-associated CD2831 levels in a wild type condition were monitored by western blot in a time-
course experiment. C. difficile 630Δerm was grown overnight in BHIS, bacterial growth was then 
centrifuged, washed once with PBS to remove all secreted proteins and resuspended in fresh 
medium. Bacterial samples were collected every 15 minutes and presence of CD2831 in the cell 
wall was investigated through western blot. As shown in Fig. 4.4, after 6 hours of growth CD2831 
was barely detectable in the cell wall due to an accumulation of ZmpI in the liquid culture. Upon 
removal of supernatant with ZmpI (medium refresh), cell-associated CD2831 promptly increased in 
the first hour to diminishing again as soon as the protease ZmpI accumulates into the supernatant.  
 
Fig. 4.4 | CD2831 is efficiently cleaved from the C. difficile cell wall from the protease ZmpI.  
Western blot (WB) on C. difficile 630Δerm cell wall lysate and culture supernatant (SN). First lane shows 
presence of CD2831 on the cell wall and ZmpI in the SN after 6 hours of growth in BHIS. Bacteria were then 
centrifuged and resuspended in fresh BHIS and samples were taken every 15 minutes for 75 minutes and 
processed for WB to monitoring presence of CD2831 in the cell wall and of ZmpI in the SN. Rabbit CD2831 
and mouse ZmpI anti-sera diluted 1:1000 were used to detect proteins of interest followed by secondary 
HRP-conjugated antibodies diluted 1:2000. 
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4.4 Generation of CD2831 overexpressing C. difficile strain 
 
CD2831 is poorly detected in both the supernatant and in the whole cell lysate of strain 630Δerm 
due to the very low levels of c-di-GMP in in vitro conditions. Stimuli inducing high levels of c-di-
GMP in vitro are unknown; therefore, in order to investigate the activity of CD2831 in the context 
of the bacterial cell wall, the gene was constitutively overexpressed in C. difficile. Genomic DNA 
was extracted from wild type 630Δerm and primers designed to amplify the entire 2.9 kb sequence 
of CD2831 gene, with the forward primer containing a 28 bp region corresponding to the protein 
SlpA Ribosome-binding site (RBS). SlpARBS-CD2831 was then ligated between SacI and SpeI sites of 
pRPF144 shuttle vector (under the regulation of the constitutive cwp2 promoter) generating 
pCwp2-2831 (Fig. 4.5 A). Plasmids pCwp2-empty and pCwp2-2831 were conjugated from E. coli 
SM10-lambda pir donor strain into 630Δerm. CD2831 expression in cytosolic, supernatant and cell 
wall fractions was investigated by western blot, flow-cytometry and immunofluorescence. The wild 
type strain containing only the empty vector presented CD2831 exclusively in the supernatant (Sn), 
whereas in the overexpressing strain (pCwp2-2831), CD2831 was also detected in the fraction 
containing cytosol and membranes (CM) and was associated with the cell wall (CW) (Fig. 4.5 B). 
Cell wall expression of CD2831 was also investigated and confirmed by flow-cytometry and 
immunofluorescence analysis (Fig. 4.5 C D).  
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Fig. 4.5| Overexpression of CD2831 in C. difficile 630Δerm. 
A. Schematic representation of pRPF144 vector used to overexpress CD2831 in C. difficile. B. C. difficile over-
night cultures were centrifuged and proteins released in the supernatant (Sn) were TCA precipitated. The 
Cell wall (CW) was isolated from cytoplasm and membranes (CM) and the three fractions were analyzed by 
western blot using sera against CD2831. C. Flow-cytometry analysis of CD2831 exposure: in light gray is 
showed the wild type condition (empty pCwp2), in dark gray is the overexpressing condition (pCwp2-2831). 
The negative black line peak represents the overexpressing strain stained with the only secondary antibody 
as negative control. D. The same bacteria were visualized by immunofluorescence microscopy, where nuclei 
are stained in blue (DAPI) and CD2831 is stained in green. 
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4.5 CD2831 overexpression enhances C. difficile binding to immobilized collagen 
and to native collagen produced by human IMR90 cells 
 
The adhesive properties of CD2831 observed in the experiments conducted by using the 
recombinant proteins were further explored by analyzing binding of 630Δerm constitutively 
overexpressing CD2831 (pCwp2-2831) to collagen type I, III and V. Therefore, C. difficile growth 
cultures at late-exponential phase (OD600 0.8-1) were diluted and inoculated into collagen-coated 
plates. Bacteria were allowed to adhere to collagens for one hour in anaerobic conditions. After 
removal of non-adhering bacteria, wells were fixed and adhesion of C. difficile was detected by 
immunofluorescence, using anti-sera raised against C. difficile 630. With these experiments we 
observed that overexpression of CD2831 confers significantly increased adhesiveness of C. difficile 
to immobilized collagens, compared to the wild type (containing empty pCwp2 vector) (Fig. 4.6 A). 
With similar experimental procedures we also measured CD2831 contribution to adhesion to 
collagen-producing cells IMR90. Cells were grown on 96 well-plates or chamber-slides for three 
days and were incubated with 100 µL of a C. difficile suspension at OD600 0.2 for 1 hour in anaerobic 
conditions. Samples were washed and fixed before staining with antibodies raised against C. 
difficile 630. Presence of fluorescent adhering bacteria was evaluated either by confocal 
microscopy or for quantitative analysis through the use of a fluorescence plate reader. As 
expected, CD2831 revealed to contribute to C. difficile adhesion to native collagen-producing cells 
as the overexpressing strain showed increased binding to IMR90 compared to the empty vector 
control (Fig. 4.6 B). 
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Fig. 4.6| Interaction of CD2831-overexpressing C. difficile with collagens and human fibroblasts. 
A. Adhesion of C. difficile overexpressing CD2831 (pCwp2-2831) and control (empty pCwp2 vector) 
strains to immobilized collagens type I, III and V after one hour of incubation in anaerobic 
condition. B. (Left panel) Adhesion assay in which C. difficile 630Δerm control and CD2831-
overexpressing strain were allowed to adhere to IMR90 cells for 1 hour at 37 °C in anaerobic 
conditions. Bacteria were stained by using an anti-CD630 serum followed by Alexa-fluor conjugated 
secondary antibody. Levels of collagens and cells-associated bacteria were detected by using a 
fluorescence plate reader. (Right panel) Confocal images of C. difficile 630Δerm control and 
CD2831-overexpressing strains adhering to the collagen-producing IMR90 cells, after 1 hour 
incubation at 37 °C in anaerobic conditions. 
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4.6 Contribution of CD2831 in biofilm formation 
 
As mentioned before, second messenger c-di-GMP has been shown to be involved in controlling C. 
difficile lifestyle switch from motility to sessility. Specifically, this results in the down-regulation of 
flagella and toxins in favor of an increased expression of adhesins or biofilm-related proteins. As a 
c-di-GMP-regulated adhesin, we also investigated CD2831 for playing a role in biofilm formation.  
C. difficile constitutively overexpressing CD2831 was compared to a wild type control strain biofilm 
formation on both collagen-coated plates and abiotic surface in BHIS medium supplemented with 
2% Glucose. Biofilm measurement through crystal violet assay showed a two-fold increase in 
biofilm for the CD2831-overexpressing strain compared to the control, after 24 hours (Fig. 4.7 A). 
In order to measure biofilm thickness through confocal microscopy, an increased bacterial biomass 
was required so pCwp2-2831 C. difficile and control strains were incubated for three days on glass 
chamber slides. Nuclei as well as extracellular DNA present in the matrix were stained with DAPI 
and Z-stack confocal microscopy images confirmed a two-fold increase in thickness of bacterial 
biofilm (Fig. 4.7 B). 
To modulate CD2831 expression levels more precisely, plasmid pTet-2831, carrying CD2831 under 
the control of the pTet-inducible promoter, was constructed and introduced into the wild-type 
630Δerm strain. Expression was then induced by a range of anhydrotetracycline (ATc) 
concentrations, and CD2831 levels were determined by immunoblotting. pTet promoter 
controlling CD2831 was induced with ATc (10, 20, 50 and 100 ng/ml) and biofilm formation was 
measured after 24-hour of growth on a plastic surface. The biofilm was then measured by Crystal 
Violet assay, which showed that C. difficile biofilm increased proportionally to the expression of 
CD2831 (Fig. 4.7 C). 
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Fig. 4.7 | CD2831 contribution to biofilm formation. 
A. Crystal violet assay on C. difficile 24 hours biofilm on plastic and collagen-coated plates. Plates were 
coated overnight at 4°C with 10 µg/ml of collagens in PBS. Bacteria were allowed to grow overnight and 
cultures were diluted at OD600 0,1 in fresh BHIS + 2% Glucose in plastic and collagens well and biofilm 
formation was allowed for 24 hours. Absorbance corresponding to crystal violet extracted dye from biomass 
was measured with a plate reader. B. 3 days C. difficile biofilm on chamber slides was stained with DAPI and 
thickness of biofilm Z-stack was measured through confocal microscopy. C. WB showing CD2831 expression 
in bacterial lysates and supernatants of C. difficile pTet-2831 after induction with 0, 25, 50 and 100 ng/mL of 
anhydrotetracycline (aTC) for 24 hours. The right graph shows C. difficile pTet-CD2831 biofilm measured by 
crystal violet assay for 24 hours at the tested aTC concentrations. 
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4.7 Heterologous expression of CD2831 in Lactococcus lactis surface results in an 
increased adherence to collagen and biofilm formation 
 
A useful tool to demonstrate putative adhesive properties of proteins of interest is the 
heterologous expression on the surface of Lactococcus lactis (Tulli et al. 2013; Buccato et al. 2006; 
Sinha et al. 2000; Arrecubieta et al. 2007). We therefore constitutively expressed CD2831 on L. 
lactis surface using vector pAM401 and we evaluated the heterologous protein contribution to the 
adhesion. Protein anchoring to L. lactis cells was achieved by substituting the original cell wall 
anchoring motif of CD2831 with a previously described motif (Edwards et al. 2008) (Fig. 4.8 A).   
We applied immunofluorescence microscopy and flow-cytometry to confirm that export of CD2831 
on L. lactis surface was successfully obtained. This allowed us to generate a strain in which CD2831 
was exclusively cell wall-associated. Moreover, we were able to observe during bacterial liquid 
culture an aggregation phenotype in bacteria expressing CD2831 that was observable also by 
fluorescence microscopy (Fig. 4.8 B). 
L. lactis expressing CD2831 was investigated for its binding activity to collagen-producing cells and, 
as observed for C. difficile, expression of CD2831 conferred an advantage in binding to IMR90 
human fibroblasts. Moreover, a pre-incubation of L. lactis with 0,1% CD2831 anti-sera was 
sufficient to reduce CD2831-expressing L. lactis- adhesion to IMR90 reaching the same level as wild 
type L. lactis (Fig. 4.8 C). 
The L. lactis heterologous system was also employed to study the contribution of CD2831 in 
bacterial biofilm formation. As for C. difficile, L. lactis expressing CD2831 and control strains were 
allowed to grow in biofilm on abiotic surface for 24 hours. Crystal violet assay showed that also in 
L. lactis bacterial background the overexpression of CD2831 contributes to increase biofilm 
formation (Fig. 4.8 D). 
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Fig. 4.8| L. lactis as heterologous system to study CD2831 adhesive properties. 
A. Schematic representation of the vector pAM401 used to express CD2831 on L. lactis surface. The sequence coding for the leader peptide and the 
LPXTG-motif at C-terminal of the C. difficile gene are substituted with the same regions of the GAS M1 gene (1–129 bp and 1348–1455 bp 
respectively), to ensure the surface exposure in L. lactis. B. Flow-cytometry (left) and fluorescence microscopy (right) of L. lactis showing surface 
exposure of CD2831. C. L. lactis strains were allowed to adhere to matrix-producing human IMR90 fibroblasts for 1 hour at 37 °C. Data show the 
contribution of CD2831 in adhesion of L. lactis to cells and inhibition of L. lactis expressing CD2831 adhesion after pre-incubation of bacteria with 0.1 
% CD2831 anti-serum for 1h. D. L. lactis strains were allowed to grow on biofilm on abiotic surface for 24 hours, bacterial biomass was measured by 
crystal violet and absorbance at 595 nm was measured. 
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4.8 CD2831 binds to human complement C1q preventing C1 complex formation 
 
In addition to binding to matrix components, members of MSCRAMMs family from Gram-positive 
bacteria are also known to bind to human complement C1q and act as inhibitors of the classical 
complement activation pathway (Kang et al. 2013). As CD2831 can be classified within this family 
of proteins, we tested recombinant CD2831 full-length protein binding to human C1q. ELISA test on 
immobilized C1q were performed and a dose-range binding activity of CD2831 towards C1q was 
registered as shown in figure 4.9 A. CD2831/C1q interaction was investigated also through 
Transmission Electron Microscopy (TEM). CD2831 displays a “comma-like” shape and notably, 
when incubated in a 1:1 ratio with human C1q, binding of CD2831 to the C1q stalk (also known as 
“collagen-like” region) was detected (Fig. 4.9 B). 
Host adaptive immune response against bacteria starts with C1q binding to the Fc region of 
antibodies surrounding the bacterial surface. This initiates the complement cascade via classical 
pathway that proceeds with the C3b deposition on the bacterium, allowing its recognition from 
macrophages. To initiate this immune defense mechanism, C1q stalk must be recognized by two 
other molecules called C1s and C1r; all together these proteins interact and form the C1 complex, 
which activates the classical pathway of the complement cascade (Fig. 4.10 A). To investigate a 
possible interference of CD2831 in the C1 complex formation, we performed ELISA tests on 
immobilized IgM in which we measured C1q, C1s and C1r deposition in presence of different 
concentration of recombinant CD2831. ELISA tests showed that recombinant CD2831 binding to 
C1q stalk reduces C1s and C1r deposition on IgM-associated C1q and therefore C1 complex 
formation is compromised (Fig. 4.10 B).  
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Fig. 9| Interaction of CD2831 with human complement C1q. 
A.  ELISA plates coated with 10 µg/ml of purified human complement component C1q were incubated with 
several dilutions of recombinant CD2831 (15 nM-1 µM) for 1 hour. The experiment shows a dose-
dependent binding activity of CD2831 to human C1q. C. difficile recombinant toxin B and Cwp25 proteins 
were used as controls. B. Transmission Electron Microscopy images showing CD2831 (white arrows), human 
C1q and CD2831/C1q in 1:1 ratio. The lower panels show drawings of CD2831 (blue) interacting with the 
stalk region of C1q (red). 
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Fig. 4.10| C1 complex formation is abolished in presence of CD2831 
A. Drawing reassuming complement activation via classical pathway: C1 complex, consisting of C1q 
interacting with two molecules of C1s and C1r, initiates the complement cascade. C1q recognizes IgM or 
certain subclasses of IgG complexed with antigens on the bacterial surface. Such binding of C1q leads to 
conformational changes in the C1q molecule, which activates the associated C1r molecules. Active C1r 
cleaves the C1s molecules, activating them. Active C1s splits other components of the cascade, which 
eventually leads to bacterial opsonization and lysis. B. ELISA plates coated with 10 µg/ml purified human 
IgM were incubated with 1% Normal Human Serum (NHS) and different concentrations of recombinant 
CD2831. After 1 hour, deposition of human C1s and C1r was measured. 1% C1q-depleted serum (C1q-dpl) 
was used as negative control.   
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5 DISCUSSION 
 
 
Bacterial infections involve binding of pathogens to ligands located on the surface of host cells and 
in the extracellular matrix (Cue et al. 1998; Talay et al. 2000; Margarit et al. 2009). In an intact 
healthy tissue, ECM is not exposed to the environment and may not be accessible for interaction 
with microbial MSCRAMMs. Characteristic of C. difficile pathogenesis is the disruption of intestinal 
epithelial tight junctions caused by the glycosylating toxins TcdA and TcdB with the consequent 
exposure of the underlying ECM (Pothoulakis 2000). In these conditions, MSCRAMMs can bind to 
ECM ligands, such as fibronectin or collagen and thus operate as important virulence factors. To 
date, high-molecular weight S-layer protein (HMW-SLP) and Collagen-binding protein A (CbpA) of 
C. difficile have been described as surface proteins that are able to bind to collagen and that could 
be implicated in this mechanism (Calabi et al. 2002; Tulli et al. 2013). CD2831 is another collagen-
binding protein of C. difficile whose presence on the bacterial surface is tightly regulated by the 
endogenous protease ZmpI that is abundant in low intracellular c-di-GMP levels conditions and 
efficiently cleaves CD2831, allowing its release in the extracellular milieu.  
First, we analyzed CD2831 protein sequence and we located the two predicted collagen-binding 
domains. Then we cloned and expressed the full-length CD2831, two subdomains containing 
individual Collagen-binding domain (CBD) and three other CD2831 subdomains containing both 
CBDs in combination with additional portions of the protein. Therefore we tested the recombinant 
proteins in collagen-binding assays. Our experiments confirmed CD2831 as a protein able to bind 
to Collagen type I, III and V and to native collagen produced by human cells and similar results 
were obtained for subdomains containing both CBDs confirming that the minimal domain 
mediating the interaction to collagen resides in the two predicted collagen-binding domains. 
Interestingly, in these experiments, the recombinant proteins presenting the single collagen-
binding domain, showed higher affinity for collagen compared to the full length CD2831. Our 
hypothesys is that this result could be due to a better exposure to the ligand of the collagen-
binding domain when the protein is halved.  
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When grown in vitro, C. difficile c-di-GMP levels have been shown to be almost undetectable and 
so are CD2831 levels on the bacterial cell wall (Hensbergen et al. 2015; Peltier et al. 2015). 
Physiological stimuli increasing c-di-GMP levels are still unknown but it is clear that it coincides 
with the switch of C. difficile to a sessile lifestyle, as c-di-GMP positively regulates adhesins such as 
TFP and negatively controls flagellar motility. Presence of bile salts as a signal upstream c-di-GMP 
regulations has been described for Vibrio Cholerae (Koestler and Waters 2014). Nevertheless, 
incubation of C. difficile with bile acids mixtures did not drive c-di-GMP increase in our 
experimental conditions (data not shown). Overexpression of diguanylate cyclases and genetic 
depletion of phosphodiesterases are the approaches followed in several studies for increasing c-di-
GMP levels in vitro in C. difficile. However, in this condition the bacterial cell wall will be 
dramatically changed by the effects of c-di-GMP on many proteins and this could not be the 
optimal asset for studying single protein functionality. Our approach was to overexpress CD2831 in 
C. difficile and although a considerable amount of the protein was still cleaved by ZmpI and 
released from the cell wall, collagen-binding activity toward immobilized collagens and native 
collagen produced by human cells was confirmed by comparing the overexpressing strain with the 
wild type. 
In order to overcome protease cleavage and release of CD2831 by the ZmpI protease, which 
targets also the putative adhesin CD3246, we employed the heterologous expression of CD2831 in 
L. lactis cell wall and confirmed collagen binding activity of CD2831 also in this strain. The increase 
of L. lactis-CD2831 adhesion to collagen-producing cells was reversed upon addiction of CD2831 
anti-sera. Results obtained using the Lactococcus system suggest that also in C. difficile, bacterial 
adhesion to collagen could be mediated by the cell wall-anchored form of CD2831. 
Other MSCRAMMs of Gram-positive bacteria, such as the fibronectin-binding protein FbsC of 
Group B streptococcus, have been shown to be involved in host epithelium invasion and in in vitro 
biofilm formation (Buscetta et al. 2014). This, together with positive regulation of CD2831 from c-
di-GMP, which also positively modulates C. difficile biofilm, drove us to investigate CD2831 as 
possibly implicated in biofilm formation. We addressed this hypothesis by comparing CD2831-
overexpressing strain with C. difficile wild type in their ability to form biofilm in vitro and we 
showed that increasing expression of CD2831 raised bacterial biomass formation. Also, we were 
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able to observe this phenotype in the L. lactis expressing CD2831. This could be reasonably 
explained as result of an increased aggregative phenotype in bacteria overexpressing CD2831. 
Interestingly, biofilm assay using C. difficile overexpressing CD2831 resulted in increased bacterial 
biomass not only on collagen, but even in not-coated plastic wells. This suggests that CD2831 
contribution to biofilm formation is presumably not limited to increase the first attachment to the 
surface and that this protein plays an active role during the bacterial biofilm construction. 
Kang and co-authors recently showed that the MSCRAMM Cna protein from Staphylococcus aureus 
and other similar Gram-positive adhesins, can also interfere with the complement cascade 
activation by interacting with human complement C1q (Kang et al. 2013). Host adaptive immune 
response against bacteria starts with C1q binding to the Fc region of antibodies surrounding the 
bacterial surface. This initiates the complement cascade via classical pathway that proceeds with 
the C3b opsonization of the pathogen and the associated enhanced phagocytosis. Complement 
cascade also brings to the generation of chemotaxis factors such as C3a and C5a involved in 
phagocytes recruitment as well as lysis of the pathogen by formation of the membrane attack 
complex on the pathogen surface. To initiate this immune defense mechanism, C1q stalk must be 
recognized by two other molecules called C1r and C1s. Association of these proteins leads to the 
formation of the C1 complex, which activates the classical pathway of the complement cascade 
(Wallis et al. 2010). Cna/C1q interaction was shown to inhibit C1r recognition of C1q and 
complement activation via classical pathway (Kang et al. 2013). In light of the similarity of Cna with 
our protein of interest, we investigated CD2831 binding to C1q. Besides confirming a dose-range 
affinity of CD2831 to human C1q, we also visualized the complex by transmission electron 
microscopy (TEM). Notably, TEM analysis showed CD2831 interacting with the collagen-like 
domain of the C1q protein stalk, which is the region where the C1r and C1s associate to form the 
heterotetramer (C1r2C1s2). We performed ELISA tests using human serum on immobilized IgM, in 
which we measured C1q, C1s and C1r deposition in presence of different concentration of 
recombinant CD2831. Whereas C1q recognition of IgM is not altered by the presence of CD2831 
(data not shown), we were able to demonstrate that recombinant CD2831 binding to C1q stalk 
reduced C1s and C1r deposition on IgM-associated C1q. In presence of CD2831, C1 complex 
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formation is therefore abolished and complement cascade via classical pathway can not be 
activated. 
Importantly, in the late 1980s, a role for C1q independent from complement activation emerged 
with the observation that immobilized C1q, in the absence of C1r and C1s, triggered an 
enhancement of FcγR-mediated phagocytosis when targets were coated with a sub-optimal 
concentration of antibody (Bobak et al. 1987). Moreover, this activity required the collagen-like tail 
of C1q and extended to enhancement of CR1-mediated phagocytosis (Bobak, Frank, and Tenner 
1988). These observations suggest that microbial MSCRAMMs binding to C1q is beneficial even 
during early stages of infection when production of anti-microbial antibodies is still not efficient 
and that employment of this mechanism could be crucial for bacteria to evade host immune 
response. 
 
In conclusion we have characterized the novel collagen-binding protein CD2831 that contributes to 
bacterial adhesion to the host and to biofilm formation. On the other hand CD2831, with its 
complement inhibition activity, represents for C. difficile a defense weapon from the immune 
system. 
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